Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today publishes its financial agenda for the year 2020.

The publications will take place after the close of the Euronext Paris markets, unless otherwise stated. These dates are given for information only, they are subject to change if necessary.

January 27, 2020: Cash update as of December 31, 2019

April 9, 2020: 2019 annual financial results

April 20, 2020: Cash update as of March 31, 2020

June 19, 2020: Annual General Meeting

July 9, 2020: Cash update as of June 30, 2020

September 29, 2020: Financial results for the 1 st half 2020

October 15, 2020: Update on cash at September 30, 2020

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical stage biopharmaceutical company from the CEA, which develops drug candidates for the treatment of diseases of the nervous system. THERANEXUS has identified the major role of non-neuronal cells (otherwise called 'glial cells') in the response to psychotropic drugs (targeting neurons). The company is a pioneer in the design and development of drug candidates that act on the interaction between neurons and glial cells. Theranexus has 3 programs under clinical development: THN 102, in phase 2 clinical trial, to combat daytime sleepiness disorders in Parkinson's disease, THN201 in phase 1b, for the treatment of cognitive disorders in Alzheimer's, and THN 101, in a phase 1a study in patients with neurological pain. The unique and patented technology exploited by THERANEXUS aims to increase the effectiveness of psychotropic drugs already approved and marketed by combining them with a glial cell modulator. This strategy of combining repositioned medicines allows it to significantly reduce development time and costs and considerably increase the chances of market access for its medicines.

Proprietary and adaptable, the THERANEXUS platform allows the generation of different proprietary drug candidates with high added value in several indications.

Contact:

Tel: 33 (0) 6 07 76 82 83

Email: fportejoie@fp2com.fr

(C) 2020 Electronic News Publishing, source ENP Newswire